https://abatacept0.com/liver-h....air-transplant-for-g
To address the unmet importance of TNBC treatment, we recently determined that tissue factor (TF) is a good surface target in 50-85% of patients with TNBC and developed a second-generation TF-targeting antibody-like immunoconjugate (known as L-ICON) for preclinical treatment of TNBC. Making use of the chimeric antigen receptor (CAR) method, right here we develop and test TF-targeting CAR-engineered normal killer (TF-CAR-NK) cells that co-express CD16, the Fc receptor (FcγI
Like
Comment
Share
